Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H13N7S |
| Molecular Weight | 359.408 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(C=N1)C2=NN3C(SC4=CC=C5N=CC=CC5=C4)=NN=C3C=C2
InChI
InChIKey=BCZUAADEACICHN-UHFFFAOYSA-N
InChI=1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3
| Molecular Formula | C18H13N7S |
| Molecular Weight | 359.408 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22547164
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22547164
SGX523 is a selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase. SGX523 was able to inhibit HGF-induced cell migration and cell scatter. SGX523 inhibition of MET in vivo was associated with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers. The clinical development of SGX523, however, was discontinued at Phase I due to renal toxicity manifested by an early rise of serum blood urea nitrogen and creatinine.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. | 2009 Dec |
|
| Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. | 2010 Aug |
|
| An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. | 2010 Jan |
|
| MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. | 2010 Sep 1 |
Patents
Sample Use Guides
In a phase I clinical trials SGX523 was administered on an intermittent schedule at a starting dose of 60 mg PO BID for 14 days followed by 7 days of rest. The second protocol explored a continuous 28-day dosing schedule with SGX523 administered at a starting dose of 20 mg PO BID for 28 days without rest.
Route of Administration:
Oral
To investigate cell migration, A549 cells were plated in 12-well plates (6 × 104 per well) and incubated to confluence. A channel was introduced into the monolayers by scratching with a pipette tip. Various dilutions of the compound were added in starve medium in the presence and absence of HGF (90 ng/mL). Twenty-four hours later, wells were checked for cell migration. Cells were stained and visualized. SGX523 was active in prevention cells migration at concentrations above 50 nM
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:24:38 GMT 2023
by
admin
on
Sat Dec 16 08:24:38 GMT 2023
|
| Record UNII |
WH8SQN09KJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1022150-57-7
Created by
admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
|
PRIMARY | |||
|
90624
Created by
admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
|
PRIMARY | |||
|
WH8SQN09KJ
Created by
admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL1236107
Created by
admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
|
PRIMARY | |||
|
DTXSID70647300
Created by
admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
|
PRIMARY | |||
|
DB06314
Created by
admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
|
PRIMARY | |||
|
C74062
Created by
admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
|
PRIMARY | |||
|
24779724
Created by
admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
